
    
      The study group (n=62) will be switched from CNI to everolimus while the control group (n=62)
      will get a general reduction of the CNI-based immunosuppression. Follow-up and duration of
      intervention per patient will be 24 months, duration of the trial 72 months including 4 years
      of recruitment.
    
  